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Abstract
Choriocarcinoma and placental site trophoblastic tumor (PSTT) 
are rare varieties of gestational trophoblastic disease (GTD). 
PSTT alone constitutes about 1-2% of all trophoblastic tumors, 
which presents at early reproductive age and the serum beta-
hCG level is much lower than choriocarcinoma. This tumor 
usually invades the myometrium and its depth of penetration is a 
prognostic factor. The first case report is regarding a 33-year-old 
woman with vaginal bleeding 3 months after abortion. The 
ultrasound exhibited heterogeneous and hypervascular mass 
related to previous cesarean scar. Serum beta-hCG level was 
67 mIU/ml and chemotherapy was administered. However, due 
to severe vaginal bleeding and no regression in mass size, total 
abdominal hysterectomy was performed. Histopathological 
examination and IHC staining confirmed PSTT from previous 
cesarean section. The second case report is regarding a 
33-year-old woman with cervicoisthmic choriocarcinoma, which 
was mistaken as cesarean scar pregnancy. The ultrasonography 
and elevated serum beta-hCG level suggested cesarean scar 
pregnancy. The patient was treated with methotrexate without 
any effect. Eventually, cervicoisthmic choriocarcinoma was 
detected after hysterectomy. A diagnostic error was made leading 
to possible uterus perforation along with incorrect chemotherapy 
that resulted in a life-threatening condition. It is concluded that 
PSTT and choriocarcinoma are the two important differential 
diagnoses of sustained elevated beta-hCG when imaging 
evidence is also suggestive. Although PSTT and cervicoisthmic 
choriocarcinoma are rare, they do exist and are on the rise. 
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What’s Known
•	 Cesarean	 scar	 placental	 site	
trophoblastic tumor (PSTT) and 
cervicoisthmic choriocarcinoma are rare 
conditions.




cesarean scar is reported.
•	 It	 is	 strongly	 recommended	 to	
suspect cesarean scar placental site 
trophoblastic tumor and choriocarcinoma 
to avoid delays in an accurate treatment 
plan.
Introduction
Placental site trophoblastic tumor (PSTT) constitutes about 
1-2%	of	all	trophoblastic	tumors.	About	75%	of	the	cases	occur	
following	a	normal	pregnancy,	17%	following	abortion,	and	only	
5%	of	the	cases	occur	following	molar	pregnancy.1 It presents at 
early	 reproductive	age	and	 the	 serum	beta-hCG	 level	 is	much	
lower than choriocarcinoma.2 This tumor usually invades the 
myometrium and its depth of penetration is a prognostic factor. 
PSTT is a very rare condition and a PSTT from previous cesarean 
scar has only been reported twice.1,3 Herein, for the third time 
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ever, a case of PSTT from previous cesarean 
scar is reported (first patient). 
Choriocarcinoma is another rare variety 
of gestational trophoblastic disease. Most 
choriocarcinomas are preceded by a complete 
mole	 that	 occurs	 in	 about	 1-2%	 of	 complete	
moles. Other cases of choriocarcinoma 
occur following partial mole (a very unusual 
occurrence),	 ectopic	 pregnancy,	 non-molar	
abortion, or term pregnancy.4	 Extrauterine	
choriocarcinoma has been reported rarely and 
the most common location is in the uterine 
cervix.5	 Untreated	 choriocarcinoma	 is	 a	 life-
threatening condition; however, it is often 
chemo-sensitive.	 Nevertheless,	 incorrect	
chemotherapy and insufficient treatment may 
lead to cure delay and metastasize. When 
choriocarcinoma	 is	 located	 extrauterine,	 its	
exact	diagnosis	 is	very	difficult.	As	part	of	 the	
second case report, we present a cervicoisthmic 
choriocarcinoma, which was mistaken as 
cesarean scar pregnancy.
The patients described in this case report 
referred	 to	 Vali-Asr	 Hospital,	 Imam	 Khomeini	
Hospital	Complex,	Tehran	University	of	Medical	
Sciences, Tehran, Iran. 
Case Report
First Patient
A	 33-year-old	 woman	 referred	 to	 the	
emergency	 ward	 of	 Vali-Asr	 Hospital	 with	
complaints of amenorrhea and irregular spotting. 
Her past medical history was unremarkable. 
The patient had one cesarean delivery and 
one	 spontaneous	 abortion	 3-	 and	 1-year	 ago,	
respectively. She was at 7 weeks of gestation with 
last menstrual period date. Her pregnancy was 
spontaneous and twins. A recent transvaginal 
ultrasound revealed dichorionic diamniotic twin 
pregnancy with normal fetal heart rate. She 
experienced	a	sudden	vaginal	bleeding	and	one	
fetus was aborted.
Vaginal ultrasound was performed and 
the demised fetus was detected in the lower 
segment of the uterus with a subchorionic 
hematoma. Uterine curettage revealed products 
of conception. She had amenorrhea for 3 months 
after curettage, but irregular spotting occurred 
and continued for 1 month. Consequently, the 
patient	 was	 referred	 to	 Vali-Asr	 Hospital.	 On	
admission, there was no significant abnormality 
on	 her	 physical	 examination	 and	 vital	 signs	
were stable.	 Only	 spotting	 from	 closed	 cervix	
was	 detected	 on	 speculum	 examination.	 The	
laboratory results were as follows: Hemoglobin 
11/2	 mg/dl	 (11-14),	 hematocrite	 34/1	 (34-38),	
and	beta-hCG	67	mIU/ml.
A Doppler vaginal ultrasound showed that the 
uterus size was 35×49 mm and the endometrial 
thickness was 5 mm. There was a heteroechoic 
and hypervascular mass from previous 
cesarean section scar (figure	 1).	 Serum	 beta-
hCG level also raised to 93 mIU/ml one week 
later. There were several differential diagnoses, 
such as cesarean scar pregnancy, retention 
placenta accreta, and gestational trophoblastic 
disease. Actinomycine was prescribed to the 
patient	because	it	was	believed	that	the	above-
mentioned differential diagnoses were sensitive 
to chemotherapy. Four courses of actinomycine 
2 mg were administered in consecutive 2 weeks. 
The patient had a strong desire to save her 
fertility and did not accept surgery. After three 
courses	 of	 actinomycine,	 the	 serum	 beta-hCG	
level returned to zero. Hence, the remaining 
course of chemotherapy was continued. Two 
weeks later, the patient presented severe vaginal 
bleeding. On admission, the blood pressure was 




laboratory tests were as follows: Hemoglobin 
8/3 mg/dl, hematocrite 23/7, platelet count 
153,000 and coagulation profile was normal, 
and	beta-hCG	was	0/7mU/ml.
The patient received 2000 cc normal saline 
infusion and 2 units packed red blood cells. 
Doppler	 ultrasound	 exhibited	 hypervascular	
heteroechoic mass 33×41 mm, similar to 
previous cesarean section scar. There was no 
evidence of regression in vascularity or size 
of the mass located in the cesarean section 
scar in comparison with the imaging before 
chemotherapy.	 Vascular	 resistance	 index	
(RI) was 0/37 and the sinologist suggested 
placental site trophoblastic tumor. There were no 
Figure 1: Sonography of the first patient showing 
heteroechoic mass from previous cesarean section scar.
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metastatic lesions in other parts of the body, such 
as liver, lung, and brain. After consultation, the 
patient agreed with hysterectomy. Laparatomy 
was performed and no significant lesion in 
abdominopelvic	 exploration	 was	 observed.	
There was a normal size uterus with a regular 
surface,	except	for	the	previous	cesarean	section	
scar location, which was slightly enlarged and 
protruded. Total abdominal hysterectomy was 
performed and the ovaries were preserved to 
save the endocrine function. On the cut section 
of the specimen, a brownish irregular friable 
mass was detected (figure 2). The operation 
and the recovery period were uneventful and the 
patient was discharged after 4 days.
On	microscopic	examination,	histopathological	
dominant pattern was the large trophoblastic 
cells with eosinophilic cytoplasm and 
pleomorphic nuclei that invaded the myometrium 
(interdigitating pattern of myometrial invasion) 
with strong immunoreactivity for human placental 
lactogen (HPL) and focal immunoreactivity for 
beta-hCG	absence	of	 immunoreactivity	 for	p63	
(a useful feature in the differential diagnosis 
with epithelioid trophoblastic tumor). The Ki67 (a 
proliferating	marker)	was	up	to	12%.	The	depth	
of	invasion	to	myometrium	was	85%.	The	mitotic	
rate was 7 per 10 high power fields. Finally, PSTT 
was confirmed (figure	3).	Serum	beta-hCG	and	
HPL were checked consecutively for 8 months. 
All measurements were in the normal range and 
the	 patient	 is	 presently	 symptom-free	 without	
any evidence of the disease. Written informed 
consent was obtained from the patient.
Second Patient
A	 33-year-old	 woman	 referred	 to	 Vali-Asr	
Hospital with complaints of irregular abnormal 
uterine bleeding. She had two pregnancies 
within 7 years. The first was a cesarean 
delivery due to malpresentation and the second 
(9 months before admission) was a miscarriage 
that led to curettage at 8 weeks of gestation. 
Her past medical history was unremarkable. 
On admission, the patient was stable and 
there were no significant issues in her routine 
examination.	 In	 vaginal	 speculum	 test,	 cervix	
was mid and closed with short spotting from it. 
The	uterus	and	adenxes	were	not	tender	in	deep	
bimanual palpation. The laboratory results were 
as follows: Hemoglobin 12/3 mg/dl, hematocrite 
35/8,	 platelet	 count	 143,000,	 and	 beta-hCG	
3,664 mIU/ml. 
Vaginal sonography revealed an empty uterus 
cavity	with	a	closed	cervix.	Endometrial	thickness	
was 12 mm. There were no abnormalities in 
the tubes or ovaries, but there was a focal 
heterogeneity 41×30 mm in the previous 
cesarean section scar that had a low resistance 
index	(RI)	in	Doppler	waves	(RI:	0/29).	Magnetic	
resonance imaging (MRI), with and without 
contrast, also confirmed the mass 40×30 mm in 
the previous cesarean section scar. 
Based on laboratory tests and imaging 
evidence, cesarean scar pregnancy (CSP) was 
diagnosed. In the absence of CSP treatment, 
according to a standard protocol, chemotherapy 
was recommended. Beforehand, the patient 
was debriefed regarding the advantages and 
disadvantages	 of	 chemotherapy.	 Methotrexate	
1 mg/kg (68 mg) was administered intravenously 
every	 48	hours	 and	 the	 serum	beta-hCG	 level	
was measured sequentially. On the first day of 
the	 chemotherapy,	 the	 serum	 beta-hCG	 level	
was 3,664 mIU/ml; however, it was reduced to 
794 mIU/ml on the 8th day and was checked 
again a week later. Unfortunately, despite a good 
response	to	methotrexate	along	with	4	courses	of	
chemotherapy,	the	serum	beta-hCG	level	raised	
to 4,325 mIU/ml 7 days later. Ultrasonography 
was performed and there was no change in the 
Figure 2: Anterior aspect of the uterus of the first patient.
Figure 3: IHC staining of the first patient showing strong 
immunoreactivity for HPL and focal immunoreactivity for 
beta-hCG.
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size of the mass and was still hypervascular. 
The distance to the serosal surface was 2 mm 
and deep penetration to myometrium was 
detected. Considering the ineffectiveness of 
chemotherapy, a surgery was planned for the 
definite treatment of CSP. The patient was 
consulted regarding the consequence; however, 
she had no desire to preserve her fertility and 
accepted the inevitability of hysterectomy during 
the operation. A midline incision was used to 
access the abdominal cavity. There were no 
abnormalities	in	the	abdominopelvic	exploration.	
The ovaries and tubes appeared normal and there 
was a bulged (largest size: 5 cm) in the anterior 
and inferior segments of the uterus just below 
the bladder reflection. The parametrium was 
fragile, particularly on the left side. The serosal 
surface was intact, but due to the location of the 
mass, uterus preservation seemed impossible. 
Consequently, total abdominal hysterectomy 
was performed. Considering the patient’s age, 
the ovaries were saved to preserve endocrine 
function. The dissected uterus is shown in 
figure 4. The recovery period was uneventful 
and the patient was discharged 13 days after 
hospitalization.	 The	 serum	 beta-hCG	 level	 on	
the third day after hysterectomy was 30 mIU/ml.
Histopathological	examination	revealed	soft,	
dark-red,	 and	 hemorrhagic	 mass	 invading	 the	
uterus	 cervix	 and	 lower	 segment	 measuring	
4×5×3.5 cm. It filled the full thickness of the 
uterus	cervix	wall	and	parametrial	tissue	and	all	
surgical margins were free. Microscopically, there 
was	 plexiform	 proliferation	 of	 cytotrophoblasts	
and cyncytiotrophoblasts with the frequent 
presence of hemorrhage and necrosis without 
any villi. On immunohistochemistry (IHC) 
staining,	it	was	positive	for	the	beta-hCG	marker	
and	 Ki67	 (a	proliferation	 marker)	 was	 85%.	
Hence, as shown in figure 5, cervicoisthmic 
choriocarcinoma was diagnosed. 
Brain, lung, and liver cut scans were 
performed to detect metastatic lesions. Based 
on the international federation of gynecology 
and obstetrics (FIGO) staging system for GTD, 
the patient was in stage 1 and the score was 5 
(low-risk).	Therefore,	single-agent	chemotherapy	
was administered. After the first course of 
actinomycine,	 the	 serum	 beta-hCG	 level	
returned to zero and thus the chemotherapy was 
continued for 3 additional courses. Currently, the 
patient is asymptomatic and followed up by a 
monthly	measure	of	the	serum	beta-hCG	level.	
Written informed consent was obtained from the 
patient.
Discussion
Several	 conditions	 can	 lead	 to	 post-abortion	
hemorrhage	 and	 elevated	 serum	 beta-hCG	
levels, such as cesarean scar ectopic pregnancy 
(CSP), gestational trophoblastic disease (GTD), 
and retention placenta increta. CSP is the rarest 
subtypes of ectopic pregnancy, but nowadays the 
incidence of CSP is rising due to the increase of 
cesarean delivery in the world.1,4 GTD is a group 
of trophoblastic tumors with malignant potential. 
PSTT	constitutes	about	1-2%	of	all	trophoblastic	
tumors.	About	75%	of	the	cases	occur	following	
a	 normal	 pregnancy,	 17%	 following	 abortion,	
and	only	5%	of	the	cases	occur	following	molar	
pregnancy.2 It presents at early reproductive age 
and	 the	 serum	 beta-hCG	 level	 is	 much	 lower	
than choriocarcinoma.3,5
PSTT typically composed of fewer 
extensive	vascular	patterns	 in	comparison	with	
choriocarcinoma.6	 The	 exact	 pathogenesis	 is	
unclear, but there is a concept that suggests 
chemo-resistance	 or	 chemo-sensitivity	 of	
this tumor is due to their cell types.7,8 PSTT 
usually invades the myometrium and its depth 
of penetration is a prognostic factor. The use 
of immunohistochemistry (IHC) staining for 
definite diagnosis of GTN subtypes was initially 
described by Shih.9 GTN staging, as described 
Figure 4: Cut of uterus specimen.
Figure 5: IHC staining is positive for beta-hCG marker 
and Ki67 (a proliferation marker) is 85%.
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by the international federation of gynecology 
and obstetrics (FIGO), is not solely helpful 
for the prognosis of PSTT. As mentioned by 
Schmid,10 there are several other factors which 
are important for prognosis, such as mitotic 
count	 rate,	 extensive	 coagulative	 necrosis,	
depth	of	myometrial	 invasion,	serum	beta-hCG	
level >1000 mIU/ml, age >35 years, and interval 
between antecedent pregnancy >2 years. 
Recently,	a	cut-off	for	the	lengthened	time	of	over	
4 years since pregnancy has been reported.
The first patient in the present case report 
underwent curettage after embryonic demise; she 
had amenorrhea for 3 months and then presented 
with spotting. The first pathology report revealed 
products of conception without any evidence of 
PSTT.	After	4	months,	beta-hCG	was	67	mIU/ml	
and there was a mass in the cesarean scar, which 
was hypervascular with RI=0/37 according to the 
Doppler ultrasound imaging. There were several 
differential diagnoses such as CSP, retention 
placenta	increta,	and	GTD.	In	all	these,	the	beta-
hCG is higher than normal and imaging (e.g. 
ultrasound, Doppler, or MRI) is unspecific for 
a	 definite	 diagnosis.	 Pathological	 examination	
is	mandatory	 for	 the	 confirmation	 of	 the	 exact	
disease. However, we administered actinomycine 
without histopathological confirmation. Since 
we believed that all differential diagnoses 
such as CSP, GTD, or increta are sensitive to 
chemotherapy, it was concluded that none would 
provide a satisfactory result. PSTT was not 
suspected as a differential diagnosis. PSTT is 
chemo-resistant,	but	in	this	case,	the	beta-hCG	
level responded positively to actinomycine. Low 
levels	 of	 beta-hCG	may	 be	 responsible	 for	 its	
rapid decrease, but no regression in mass size 
and severe vaginal bleeding indicated a specific 
chemo-resistance	 condition.	 Therefore,	 PSTT	
was strongly suspected and total abdominal 
hysterectomy was performed. The fact that 
histopathological confirmation (e.g. transcervical 
ultrasound-guided	 biopsy)	 is	 mandatory	 for	
careful evaluation prior to hysterectomy was 
unknown to us. PSTT is a very rare condition 
and a PSTT from previous cesarean scar has 
only been reported twice.1,3 Our encounter with 
PSTT is the third such case. 
Further significant issue in our patient was an 
early proliferation of PSTT within 3 months after 
abortion. We stained slides with IHC markers. 
The	beta-hCG	showed	 scattered	 positivity	 and	
HPL	 was	 stained	 extensively.	 Taken	 together,	
the	 level	 of	 beta-hCG,	 chemo-sensitivity,	
histopathology, and finally IHC staining results 
were most consistent with PSTT. Considering 
the age of the patient, we managed to save 
the ovaries to preserve endocrine function. The 
PSTT was in stage 1 and confined to the uterus. 
Considering good prognosis after surgery 
without recurrence in other sites, it was treated 
by	surgery.	The	10-year	survival	rate	for	people	
with	PSTT	stage	1	 is	90%.	Chemotherapy	and	
radiation are not recommended after surgery.
There are several differential diagnoses (e.g. 
cesareans scar pregnancy (CSP) and placenta 
increta) for patients with positive human chorionic 
gonadotropin (hCG) combined with imaging 
evidence such as a cervicoisthmic mass with 
empty uterus cavity. Nonetheless, without any 
response to chemotherapy alone, trophoblastic 
disease	 is	 possible.	 The	 exact	 diagnosis	 is	
essentially difficult.10 The incidence of CSP is 
rising due to the increase of cesarean delivery 
and is reported as 1 per 2,216 pregnancies.11 
There is no specific and definite strategy to treat 
CSP	 and	 chemotherapy	 with	 methotrexate	 is	
one of the options. However, the critical issue 
at	 hand	 is	 the	 life-threatening	 condition	 due	 to	
unnoticed CSP and incorrect diagnosis. Surgery 
is mandatory in the absence of any response to 
the selected medical treatment. Dilatation and 
curettage after uterine artery embolization have 
been discussed to cure CSP.12 In our patient, 
chemotherapy was chosen since we had no 
experience	 with	 uterine	 artery	 embolization	 in	
CSP. Prior to hysterectomy, our final diagnosis 
was GTD. It was only after the surgery that the 
exact	diagnosis	was	revealed	and	subsequently	
the lungs, brain, and liver were evaluated to 
identify possible metastatic lesions.
GTD is composed of abnormal proliferation 
trophoblastic cells with malignant potential. 
Choriocarcinoma is a rare subtype of GTD and 
its incidence in Asia is high and reported as 1 
per	500-1,000	pregnancies.	About	25%	of	GTDs	
occur after abortion and often mistaken as CSP 
since the symptoms and imaging evidence are 
similar.13 The pathogenesis of cervicoisthmic 
choriocarcinoma is controversial. It is suggested 
that malignant transformation of the remaining 
chorionic cells from the previous pregnancy is 
responsible for its formation. After confirmation, 
choriocarcinoma must be staged. Based on 
the international federation of gynecology and 
obstetrics (FIGO) staging system for GTD, our 
patient	was	in	stage	1	and	the	score	was	5	(low-
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•	 Prior	chemotherapy:	0	point
The patient presented in this case report had 
a score 5 and was a candidate for single agent 
chemotherapy after hysterectomy. Four courses 
of actinomycine 2 mg were used intravenously. 
Conclusion
Although PSTT and cervicoisthmic 
choriocarcinoma	are	rare,	they	do	exist	and	are	
on the rise. Specific focus should be placed on 
GTD even if other differential diagnoses are 
probable. If we had suspected cervicoisthmic 
choriocarcinoma, the hysterectomy of a 
33-year-old	woman	(second	patient	in	this	case	
report) could have been avoided with accurate 
chemotherapy	 after	 a	 fine-needle	 aspiration	
biopsy confirmation. A diagnostic error was 
made leading to possible uterus perforation 
along with incorrect chemotherapy that resulted 
in	a	life-threatening	condition.	
PSTT grows very slowly and metastasize 
occurs after several years. Therefore, 
hysterectomy can prevent future spread of the 
disease. Despite choriocarcinoma, PSTT is less 
sensitive to chemo agents. Therefore, surgery is 
recommended	even	 if	serum	beta-hCG	level	 is	
normalized. 
Conflict of Interest: None declared.
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